Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia
A phase 1/2 trial of TBI-1501 in acute lymphoblastic leukaemia, run by Takara Bio Inc., active and no longer recruiting.
Overview
Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia is a phase 1/2 interventional study registered as NCT03155191 by Takara Bio Inc., with 21 participants enrolled, started 2017-06-01 and due to reach its primary completion in 2035-03-31. Interventions recorded: TBI-1501.
Similar pages
not linked directly; found by shared links- TrialClinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialA Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialCAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialStudy of YK012 in B-cell Acute Lymphoblastic Leukemia
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialAZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialA Study of CTD402 in T-ALL/LBL Patients
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialA Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialStudy of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
Shares Acute lymphoblastic leukaemia and the tag pipeline.